IL1RL1 and asthma: However, we do show that cells carrying the asthma risk IL1RL1 protein are more amenable to the antiinflammatory effects of anti-IL1RL1 and anti–IL-33, which has important therapeutic implications for potential stratified medicine approaches, especially in light of current pharmaceutical development of an IL-33/IL1RL1 antagonist for use in asthma.